COPYPASTA from reddit research nexus

I guess it's a conspiracy of silence or a conspiracy of hypocrisy in our government or a conspiracy of ignorance....or a conspiracy of conflicting authorities.

Here's why: Psilocybin / Psychedelics generally are schedule I which is described as

>The drug or other substance has no currently accepted medical use in treatment in the United States.

However, NIH, our own National Institutes of Health, oversaw and peer reviewed by publication many studies demonstrating medical merit of nearly ALL psychedelics, but these remain as schedule 1 per the UN's convention on psychotropic substances which informs our laws and those of other countires.

Here are the studies:

• Magic mushrooms' effects illuminated in brain imaging studies -- Treats Depression
• Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. -- Treats Anxiety
• Effects of psilocybin on hippocampal neurogenesis and extinction of trace fear conditioning. -- Stimulates neurogenesis and treats PTSD
• Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. -- treats OCD
• Response of cluster headache to psilocybin and LSD. -- Treats Cluster Headaches
• Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. -- makes people more open minded and spiritual; 'Positive changes in attitudes' -- makes people kinder.
• Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness.
• Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later -- Over a year later psilocybin users report use as meaningful, positive attitudes persist after 14mo
• Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action.
• Single treatments that have lasting effects: some thoughts on the antidepressant effects of ketamine and botulinum toxin and the anxiolytic effect of psilocybin.
• Magic mushrooms' effects illuminated in brain imaging studies
• Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer
• Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin.
• Activation of serotonin 2A receptors underlies the psilocybin-induced effects on α oscillations, N170 visual-evoked potentials, and visual hallucinations.